J. Layton

First name

J.

Middle name

B.

Last name

Layton

Johannes, C. B., Beachler, D. C., Layton, J. B., Danysh, H. E., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01263-3

View

Danysh, H. E., Johannes, C. B., Beachler, D. C., Layton, J. B., Ziemiecki, R., Arana, A., et al. (2022). Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting. Drug Saf. http://doi.org/10.1007/s40264-022-01262-4

View

Spoendlin, J., Layton, J. B., Mundkur, M., Meier, C., Jick, S. S., & Meier, C. R. (2016). The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-016-0462-5

View

Burkard, T., Hugle, T., Layton, J. B., Glynn, R. J., Bloechliger, M., Frey, N., et al. (2018). Risk of Incident Osteoarthritis of the Hand in Statin Initiators: A Sequential Cohort Study. Arthritis Care Res (Hoboken). http://doi.org/10.1002/acr.23616

View

Requena, G., Ma, L., Sturmer, T., Layton, J. B., & DiBello, J. (2020). Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clin Drug Investig. http://doi.org/10.1007/s40261-020-00935-1

View